Compare NEWT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEWT | CCCC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.6M | 404.7M |
| IPO Year | 2013 | 2020 |
| Metric | NEWT | CCCC |
|---|---|---|
| Price | $12.11 | $3.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $15.33 | $12.20 |
| AVG Volume (30 Days) | 244.1K | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | 11.22 | ★ 16.45 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $13.70 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $9.59 | $1.69 |
| 52 Week High | $15.69 | $5.17 |
| Indicator | NEWT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 36.66 |
| Support Level | $11.47 | $3.40 |
| Resistance Level | $12.38 | $3.91 |
| Average True Range (ATR) | 0.29 | 0.22 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 48.18 | 1.74 |
NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.